Biopid Corporation is a bio company that was established in December 2005 for the purposes of research and development of skin disease such as atopic dermatitis, eczema, psoriasis and lung disease such as rhinitis, asthma etc.
Biopid has developed novel and effective materials on atopic dermatitis
It is a composition, *Composition for reducing the exudation of serum proteins* of which a key ingredient is the double-saturated phospholipid developed for treatment of rhinitis, asthma, chronic obstructive pulmonary diseases and noninfectious skin diseases such as atopic dermatitis and the patent registration has been completed in 17 countries of the world.
It was approved phase 2 and 3 clinical trials as a treatment for atopic dermatitis by KFDA, and it was completed clinical trials (three-phase) at 8 Korean university hospitals for the first time in Korea in 2009.
KT&G101 acquired approval of new drugs (KFDA) in nov. 2012
Also, Biopid has completed the development of cosmetics for atopic dermatitis applying the patented ingredient.
Currently, it is developing functional cosmetic for anti-aging and infant.
Biopid has a capital US$3.5M and affiliated companies, company for cosmetics distribution , for atopic medical tourism.
Atopy Medication Development History
Feb. 2005. Application of patent for *Composition for reducing blood protein exudation*
Dec. 2006. Signed transfer of technology contract with KT&G for Atopic dermatitis medication
Aug. 2008. Phase 2 and 3 of clinical trials for Atopic dermatitis medication (KT&G101) approved by Korean Food and Drug Administration
Jan. 2009. Initiation of KT&G 101 phase 2 and 3 clinical trials at 8 Korean university hospitals
(Seoul University Hospital, Yeonsei University Severance Hospital, Catholic University of Korea Uijeongbu St. Mary Hospital, Hanyang University Hospital, Chungang University Hospital, Catholic University of Korea Incheon St. Mary Hospital. Hallym University Medical Center, Soonchunyang University Hospital)
Nov. 2009. Completion of Phase 3 clinical trials of Atopic dermatitis medication (KT&G101)
Jul. 2010. Composition of final report of clinical trial of Atopic dermatitis medication (KT&G101)
Mar. 2011. Applied for NDA of Atopic dermatitis medication (KT&G101) at Korean Food & Drug Administration
Nov. 2012 KT&G101 acquired approval of new medicine for Atopic Dermatitis (KFDA)
Patent Status
*Composition for reducing the exudation of serum proteins* patent
- Applicable field : Atopic dermatitis, nasal inflammation, and asthma medication and cosmetics
- Patent registration : Korea (2009), Austria, Singapore, Russia (2010), China, EU (2011), Japan, India, Hong Kong (2012)
- Patent evaluation : U.S, Brazil, Canada
*Compound for accelerating hair growth* applied for patent
- Applicable field : Hair loss prevention / hair growth
- Patent application complete (May, 2010)
- PCT application (May, 2011)
*Patch for the treatment and relief of symptoms of skin diseases with the exudation of serum proteins* applied for patent
- Applicable field : Atopic dermatitis, Eczema, Psoriasis, Erythema, Urticaria
- Patent application complete (Jul, 2010)
- PCT application (Jul, 2011)
BPCOSMEDI is company for cosmetics distribution of BIOPID.
